So what’s next after CorE 64? Today, Toshiba at AHA announced a new study—faCTor 64—that aims to improve early diagnosis and treatment of coronary artery disease in asymptomatic diabetics who are at higher risk via cardiac CT angiography. This potentially could allow CT to be used to manage diabetic patients, based on age and gender, Toshiba said.
The Screening For Asymptomic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following CorE 64: A Randomized Control Study will be performed in conjunction with Intermountain Healthcare in Salt Lake City, Utah. More than 1,000 patients from Utah, women older than 55 years old and men over 50, will be enrolled in the study using Intermountain Healthcare’s diabetic registry of 30,000 patients. Toshiba said the healthcare system has one of the largest diabetic databases in the country.
The faCTor 64 study, for which enrollment has already begun, will use Toshiba’s Aquilion 64-slice CT system (Intermountain Healthcare has five scanners) to capture obstructive and non-obstructive, or sub-clinical, coronary heart disease data to determine the best way to treat diabetic patients. This is the same system used in the CorE 64 study. The faCTor 64 procedure is based on CorE 64 and will be conducted in partnership with Johns Hopkins University.
“Patients with diabetes have two- to four-times greater risk of cardiovascular disease than non-diabetic patients,” said Donald Lappe, MD, FACC, chief of cardiology at Intermountain Medical Center in Salt Lake City and medical director of the Intermountain Healthcare Cardiovascular Clinical Program. “This, coupled with the fact that cardiovascular death is the most common cause of mortality among Type 2 diabetics, emphasizes the importance of the faCTor 64 study. The ability to detect CHD in at-risk, asymptomatic patients will have a significant impact on the ability to improve their cardiac conditions and will help save lives.”